for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ORIC Pharmaceuticals Inc

ORIC.OQ

Latest Trade

32.58USD

Change

-1.90(-5.51%)

Volume

59,342

Today's Range

30.63

 - 

35.29

52 Week Range

18.76

 - 

40.60

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
34.48
Open
35.29
Volume
59,342
3M AVG Volume
6.32
Today's High
35.29
Today's Low
30.63
52 Week High
40.60
52 Week Low
18.76
Shares Out (MIL)
35.59
Market Cap (MIL)
1,227.25
Forward P/E
-9.48
Dividend (Yield %)
--

Latest Developments

More

Oric Pharmaceuticals Provides Corporate Update And Highlights Key 2021 Milestones

Oric Pharmaceuticals Inc Files For Offering Of Up To 4.0 Million Shares Of Common Stock - SEC Filing

Oric Pharmaceuticals Reports Proposed Public Offering Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About ORIC Pharmaceuticals Inc

ORIC Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by overcoming resistance in cancer. The Company is focused on developing a diverse pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its experience within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. Its lead product candidate is ORIC-101. The Company’s ORIC-101 is a potent and selective small-molecule antagonist of the glucocorticoid receptor (GR), which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. The Company’s second product candidate, ORIC-533, is an orally bioavailable, small-molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy-and immunotherapy-based treatment regimens. Its third product candidate, ORIC-944, being developed for prostate cancer.

Industry

Biotechnology & Drugs

Contact Info

240 E. Grand Ave., 2nd Floor

SOUTH SAN FRANCISCO, CA

94080

United States

+1.650.3885600

http://oricpharma.com/

Executive Leadership

Richard A. Heyman

Independent Chairman of the Board, Founder

Jacob M. Chacko

Chief Executive Officer, Director

Dominic G. Piscitelli

Chief Financial Officer

Christian V. Kuhlen

General Counsel

Matthew Panuwath

Chief Business Officer

Key Stats

1.57 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2020(E)

0.0K
EPS (USD)

2020(E)

-3.638
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
5.71
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up